Microbiome Movement Summit
28-30 January 2025
Barcelona, Spain
Tim Sharpington attending and presenting
At Microbiotica, we are translating clinic-led microbiome science into transformative life-changing medicines.
About Us
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Pipeline
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Platform
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.
News
- Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients 13 November 2024
- Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma 7 October 2024
Events
Microbiotica is a clinic-ready biopharmaceutical company developing a pipeline of orally-delivered live biotherapeutic products (LBPs) composed of highly-defined bacterial strains for therapeutic applications in immuno-oncology (IO) and inflammatory bowel disease (IBD).
